Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.140
-0.060 (-2.73%)
Mar 31, 2025, 9:30 AM EST - Market open
Perspective Therapeutics Revenue
In the year 2024, Perspective Therapeutics had annual revenue of $1.45M with 1.39% growth. Perspective Therapeutics had revenue of $234.00K in the quarter ending December 31, 2024, a decrease of -30.56%.
Revenue (ttm)
$1.45M
Revenue Growth
+1.39%
P/S Ratio
97.48
Revenue / Employee
$12,218
Employees
140
Market Cap
158.47M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CATX News
- 6 hours ago - Perspective Therapeutics to Participate in Upcoming April Investor Conferences - GlobeNewsWire
- 4 days ago - Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results - GlobeNewsWire
- 14 days ago - Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - GlobeNewsWire
- 17 days ago - Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga
- 4 weeks ago - Perspective Therapeutics to Present at Upcoming March Investor Conferences - GlobeNewsWire
- 5 weeks ago - Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Perspective Therapeutics to Participate in Upcoming February Investor Conferences - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire